MPoMA通过p65降解来保护肺上皮细胞受伤
Soheun Lee1, Suh Jin Yoon1, Ji Hyun Oh1
1College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea.
概括
研究人员确定了MPoMA,这是一种抑制病毒感染并防止肺上皮细胞损伤的化合物. MPoMA通过降解p65蛋白来减少炎症反应,这为治疗肺部损伤提供了潜力.
科学领域:
- 生物化学 生物化学
- 细胞生物学 细胞生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 病毒感染,尤其是COVID-19,已造成严重的肺损伤.
- 药物开发优先考虑抗病毒疗法,而不是治疗肺损伤.
- 识别保护肺上皮细胞的化合物至关重要.
研究的目的:
- 选化合物以检测它们预防病毒感染和减少肺上皮细胞损伤的能力.
- 为了确定病毒诱导的肺损伤的新型治疗剂.
- 阐明保护性化合物的作用机制.
主要方法:
- 细胞毒性测试是在抗病毒化合物库上进行的.
- 评估了病毒尖端蛋白与细胞结合的抑制.
- 测量了阿莫迪亚奎因 (AQ) 损伤的肺上皮细胞中的介乐金-8 (IL-8) 生产.
- 机理学研究涉及分析p65的蛋白质体降解和体内急性肺损伤模型.
主要成果:
- 鉴定出N-(4-(4-甲基) -3-甲基) -N-甲基胺 (MPoMA) 是病毒感染和AQ诱导的细胞损伤的非细胞毒性抑制剂.
- MPoMA抑制了IL-8,IL-6,IL-1β和纤维素的AQ诱导表达,并防止了形态损伤.
- MPoMA选择性地增强了p65的蛋白质体降解,减少了p65介导的炎症反应.
- 在体内,MPoMA证明了对LPS诱导的急性肺损伤的保护作用.
结论:
- MPoMA是缓解病毒感染和预防肺上皮细胞损伤的有希望的化合物.
- 该机制涉及p65的降解,导致减少炎症性细胞因子的产生.
- 对于急性肺损伤和相关疾病,MPoMA可能会提供治疗效益.
相关概念视频
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.8K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.8K
02:23Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
01:31The Intrinsic Apoptotic Pathway
6.5K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.5K